ESR1 and neoplasm: Late relapse in women with ER+ breast cancer is thought to result from the activation of dormant tumor cells at metastatic sites such as the bone marrow2; and about 20% of women with ER+ disease have a recurrence 15 years or more after initial diagnosis3.